Editorial review · United States
Epitalon
Source review:
Approval and product status
No FDA-approved epitalon drug product
Similar names do not mean that products have the same evidence. Epitalon, epitalon acetate, and older pineal extracts such as epithalamin are not automatically interchangeable evidence objects.
This is the status described in the dated review. It is not a live FDA database check.
What was measured in people?
- Health outcomes · Unclear
- FDA found no studies establishing insomnia outcomes for the nominated epitalon substances and route.
- Body effects · Limited
- Melatonin and cell-line findings are indirect and do not establish patient benefit.
A change in a hormone or body signal does not by itself prove a health benefit.
Limits that matter
Not independently medically reviewed. This tool does not recommend treatment.
A claim about longer life needs long-term results in people, not only laboratory mechanisms. This guide provides no injectable, sleep-treatment, or anti-aging regimen.
Still unknown: Changes in cells grown in a laboratory do not establish slower aging, longer life, cancer prevention, or improved health in people. Evidence from epithalamin cannot be reassigned to epitalon.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Exact product records in this review
These are selected records, not every product or form. A route means how a product enters the body.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
Laboratory work has reported telomere-related effects in human cell lines. Telomeres are protective ends of chromosomes. FDA's current review found melatonin-related information but no clinical insomnia studies using the nominated substances by the proposed route.
Read all Epitalon claims and their limitsSources used in the full review
A source is not support for every claim. Use the claim links above or the full review to check what each source supports.
- FDA briefing document for epitalon-related bulk drug substances
U.S. Food and Drug Administration · FDA review · 2026
Source accessed
- Epitalon and telomere length in human cell lines
PubMed · Biogerontology · Preclinical · 2025
Source accessed
- July 2026 Pharmacy Compounding Advisory Committee meeting
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed